Here, we found that MET knockdown inhibited the activity of STAT3/Akt pathway, and targeted inhibition of the STAT3/Akt pathway using ACT001 could abolish the promotion effect of MET on anlotinib-mediated DDP resistance in NSCLC cells. Here, AKT1 is linked to non-small cell lung carcinoma.